Innate Pharma (IPHA) Invested Capital (2017 - 2025)

Innate Pharma (IPHA) has 9 years of Invested Capital data on file, last reported at $1.0 million in Q4 2025.

• For the quarter ending Q4 2025, Invested Capital fell 97.63% year-over-year to $1.0 million; the trailing twelve-month figure through Dec 2025 stood at $1.0 million (down 97.63% YoY), and the FY2025 full-year result was $1.0 million, down 97.63% from the prior year.
• Invested Capital for Q4 2025 stood at $1.0 million, down from $15.9 million in the prior quarter.
• Across five years, Invested Capital topped out at $173.5 million in Q4 2021 and bottomed at $1.0 million in Q4 2025.
• The 5-year median for Invested Capital is $83.6 million (2022), against an average of $86.0 million.
• The widest annual swing landed in 2021, when Invested Capital sank 99.92%; it then advanced 0.42% in 2023.
• A 5-year view of Invested Capital shows it stood at $173.5 million in 2021, then plunged by 43.32% to $98.4 million in 2022, then increased by 0.42% to $98.8 million in 2023, then slumped by 56.91% to $42.6 million in 2024, then tumbled by 97.63% to $1.0 million in 2025.
• The last three Invested Capital figures came in at $1.0 million (Q4 2025), $15.9 million (Q2 2025), and $42.6 million (Q4 2024), per Business Quant data.

Peer Comparison